Table 1

Patient characteristics

ETA + MTXETA + LEFADA + MTXADA + LEFINF + MTXINF + LEFBiologics/MTX vs biologics/LEF p values
N44814456617436176
Age in years, mean (SD)52.6 (12.4)54.3 (11.0)53.5 (11.3)54.0 (12.9)52.4 (12.6)54.3 (14.4)0.049
Disease duration in years, median (IQR)8 (4–15)8 (5–14)10 (5–17)9 (4–16)8 (5–14)9 (5–14)0.68
% Female75.569.478.178.771.877.60.86
Rheumatoid factor positive (%)78.882.680.479.979.873.70.995
FFbH at t0, 0–100; 100  =  best56.9 (22.6)57.1 (22.9)60.1 (23.2)58.8 (23.3)54.5 (21.1)58.8 (19.9)0.73
HAQ at t0, calculated from FFbH1.6 (0.6)1.6 (0.6)1.5 (0.6)1.5 (0.7)1.6 (0.6)1.5 (0.6)n.a.
ESR at t0, mm/h, median (IQR)29 (16–50)38 (20–60)28 (16–44)30 (18–48)30 (15–51)42 (22–67)<0.0001
CRP, mg/l, median (IQR)18 (8–36)20 (9–52)14 (6–34)15 (8–33)21 (8–47)22 (12–47)0.15
DAS28 at t05.7 (1.3)5.8 (1.2)5.5 (1.2)5.7 (1.2)5.8 (1.2)6.1 (1.2)0.027
% Erosive at t079.979.079.180.382.684.70.86
% Ever treated with biologics15.09.026.920.716.99.20.006
No of previous traditional DMARD3.3 (1.4)3.3 (1.2)3.1 (1.2)3.2 (1.1)3.4 (1.4)3.7 (1.4)0.47
Mean dosage of DMARD in mg15.5 (5.1)18.8 (3.4)15.1 (4.6)19.0 (4.0)14.7 (4.9)19.2 (3.2)n.a.
% With co-morbidity71.171.563.366.165.470.70.34
Follow-up in months, median (IQR)35 (20–48)25 (17–36)23 (12–32)20 (12–30)36 (24–49)35 (23–49)<0.0001
  • Values are means and standard deviations if not otherwise specified. ADA, adalimumab; CRP, C-reactive protein; DAS28, disease activity score based on 28 joint counts; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; ETN, etanercept; FFbH, Hannover functional status questionnaire measuring functional capacity in percentage of full function; HAQ, health assessment questionnaire; INF, infliximab; IQR, interquartile range; LEF, leflunomide; MTX, methotrexate.